Our vision is to improve the treatment of severe diseases in order to provide benefits for both patients and society as a whole.
the share
%
research
production
investor information
veterinary health division
news
Oasmia Pharmaceutical Secures Financing of 108 MSEK
Oasmia Pharmaceutical AB (publ) (“Oasmia” or the ”Company”) a developer of a new generation of drugs within human and veterinary oncology, has agreed to a loan totalling 108 million SEK, of w...
Read more
Oasmia Pharmaceutical receives marketing approval for Paclical® in Kazakhstan
Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs within human and veterinary oncology, announced today that it has received marketing approval for Paclical in Kazakhst...
Read more
Oasmia Pharmaceutical AB (publ) Interim report for the period May – October 2017
Increased focus on commercialization
Read more
Oasmia has completed a private placement of new convertible instruments in a total amount of SEK 28,000,000
Oasmia Pharmaceutical AB (publ) (“Oasmia” or the “Company”) hereby announces that the Company has completed a private placement of a convertible loan in the amount of SEK 28,000,000 with an in...
Read more